STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending

Name: STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending
Start: 2026-06-06T20:54:24.000Z
Location: New Orleans

drug approval expired 100% Health

STAT News covers recent developments presented at the American Diabetes Association conference in New Orleans, focusing on triple hormone receptors and monthly obesity drugs. The article emphasizes new research and treatments related to obesity and diabetes.

🇺🇸 Location: New Orleans — Sources: 24 — First seen: 2026-06-06 — Last seen: 2026-06-10

obesity diabetes American Diabetes Association medical research health treatments

Contributing Articles

USMNT's Chris Richards on track for World Cup opener after ankle injury: 'Whatever it takes'
Yahoo Sports — 2026-06-10
Drugmaker Parabilis Soars 67% After $745 Million IPO, Placement
Bloomberg — 2026-06-10
Ethyreal starts up with $101M and takes aim at a pair of immune diseases
BioPharma Dive — 2026-06-10
Stellantis recalls over 1M Jeeps due to potential fire hazard
The Hill — 2026-06-10
Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha — 2026-06-10
Parabilis sets a record with a $670M biotech IPO
BioPharma Dive — 2026-06-10
🏥 Marcel Ruíz undergoes surgery on his knee injury
Yahoo Sports — 2026-06-10
FDA OKs first new sunscreen ingredient in more than 25 years
STAT News Health — 2026-06-09
AI is boosting accuracy for clinicians, Philips North America CEO says
Channel NewsAsia — 2026-06-09
Common drink has surprising affect on aging, study says
Harrisburg Patriot-News — 2026-06-09

STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending

Linked Entities

Contributing Articles